Sartorius Stedim North America Inc.

Sartorius Stedim North America Inc., a foreign-owned subsidiary of German multinational Sartorius Aktiengesellschaft headquartered in Bohemia, New York, supplies specialized laboratory equipment, bioreactor systems, filtration products, and related maintenance and support services to federal research and biopharmaceutical agencies as a prime contractor (98% of recent awards), competing in full-and-open procurements without set-aside designations.

The vendor's federal customer base concentrates heavily within the Department of Health and Human Services. The National Institute of Allergy and Infectious Diseases leads by combined potential value ($5.6 million across 15 awards), followed by the Food and Drug Administration ($2.6 million across 22 awards) and the National Center for Advancing Translational Sciences ($1.9 million across 12 awards). These three agencies account for approximately 60% of recent awards. A notable distinction appears between volume and dollar rankings: FDA places more awards (22) but NIAID anchors most of the dollars, reflecting NIAID's procurement of larger-ticket bioreactor systems and vaccine-production equipment while FDA procures a higher count of smaller consumables and maintenance contracts. Secondary customers include the NIH Clinical Center, the National Cancer Institute, the National Institute on Aging, and USDA Agricultural Research Service.

Sartorius Stedim North America's capability portfolio centers on original equipment manufacturer (OEM) products and services for biopharmaceutical research and biodefense manufacturing. Recent representative work includes a $4.5 million firm fixed-price purchase order from NIAID for two AMBR 250 high-throughput bioreactor systems (awarded September 2024), a $395 thousand maintenance and support agreement with the National Center for Advancing Translational Sciences for three CompacT Select automated cell culture systems (awarded September 2025), a $326 thousand purchase order from USDA Agricultural Research Service for a Biostat B bioreactor dual control unit with installation (awarded September 2024), a $548 thousand service contract with NCATS for preventative maintenance and repair on three SelecT Compact systems (awarded August 2024), and a $182 thousand installation and training contract for large-scale bioreactors supporting the USDA's biodefense medical initiative (awarded August 2024). The vendor also holds multiple standing orders and consumables agreements for bioreactor vessels, filtration products, reagents, and laboratory supplies across NIH institutes.

Recent activity has plateaued after sustained volume. The vendor received 10 awards in 2022, 14 in 2023, and 13 in 2024, but only 6 in 2025 and 2 in 2026 (as of mid-May 2026). Three awards carrying combined potential value of approximately $1 million face ultimate completion within the next twenty-four months and therefore face recompete exposure. The vendor places work under the GSA Multiple Award Schedule (4 task orders documented) but carries no presence on government-wide IDIQs or larger contract vehicles. Service Contract Inventory data, which captures federal service contracts above the $150,000 threshold, show one SCI-reportable record yielding $273 thousand in FY2024 invoiced revenue; this represents a narrow slice of the vendor's total federal work, which is dominated by goods (bioreactors, equipment, consumables) and smaller service-delivery purchase orders below SCI's $150,000 reporting floor.

The vendor operates as a prime on 115 of 117 recent awards and subcontracts on only 2 awards, both as a sub to Weems Design Studio, Inc. on NIAID Vaccine Research Center operational task orders for equipment maintenance and decommissioning work. This posture reflects the vendor's role as an OEM and equipment supplier rather than a systems integrator or services prime; federal agencies buy directly from Sartorius for its proprietary equipment and the specialized support only Sartorius can provide (sole-source procurements appear across multiple NCATS and NIAID awards, citing the vendor's status as the only authorized service provider for its own equipment).

Sartorius Stedim North America competes in Analytical Laboratory Instrument Manufacturing (NAICS 3826, primary category covering 46 awards), Electronic and Precision Equipment Repair and Maintenance (NAICS 8112, 8 awards), and In-Vitro Diagnostic Substance Manufacturing (NAICS 3826, 5 awards). PSC codes align with the capability set: Laboratory Equipment and Supplies (51 awards), Maintenance/Repair/Rebuild of Instruments and Laboratory Equipment (24 awards), Drugs and Biologicals (11 awards), and IT/Telecom Business Application Software (6 awards, primarily SIMCA software licenses). The vendor has held federal contractor status since 2008 and maintains a history of supporting critical federal research initiatives including COVID-19 vaccine development and NIAID's vaccine production programs.